Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Sanofi has signed a $326 million deal with Orano Med for radiopharma, following a similar deal made in September. Sage Therapeutics is laying off 33% of employees to support the launch of its postpartum depression drug. Bristol-Myers Squibb's Opdivo showed a progression-free survival advantage over Pfizer's Adcetris in a late-stage study for Hodgkin's lymphoma. Kezar Life Sciences has cut its lupus program after patient deaths and is now focusing on autoimmune hepatitis. The Institute for Clinical Research is researching ways to extend healthy lifespan. Other news includes GSK and Viiv touting the effectiveness of a long-acting HIV prep, Bavarian Nordic's Jynneos eliciting a robust antibody response in adolescents, and AbbVie winning approval for an advanced Parkinson's treatment. Takeda has walked away from a partnership for Huntington's disease after investing $260 million.